Abstract: Methods for preparing products containing moisture-sensitive materials, including biological materials such as proteins, peptides or live cells, comprising at least the steps: (i) providing a coating liquid comprising at least one active, a sugar polymer and a water soluble/miscible solvent; (ii) providing a quantity of microparticles comprising at least water soluble gel forming solid particles; (iii) fluidizing said quantity of microparticles within a processing chamber of a of a suitable apparatus to form a fluidized bed of said microparticles; (iv) spraying said coating liquid onto said fluidized bed from beneath the fluidized bed to coat said microparticles therewith under saturated moisture conditions; and (vi) allowing coated microparticles to dry, are described. Also described are compositions and uses.

Abstract: A method of manufacturing a bioactive fluid dose on an ingestible sheet, comprising the steps of advancing the ingestible sheet to a dispense position, and activating a fluid ejector to dispense essentially a drop of a bioactive fluid onto the ingestible sheet.

Abstract: Disclosed is a chewing gum composition capable of eliminating nicotine component from the body of a person chewing the chewing gum. Such a chewing gum composition functions to convert the nicotine produced in a human body after smoking to cotinine and to discharge the cotinine into urine. Accordingly, by chewing the chewing gum of the present invention, not only nicotine can be eliminated from the body, but also the incidence of cancer due to nicotine can be largely reduced.

Abstract: A method for producing a chewing gum with a controlled release of an antimicrobial agent, as well as the chewing gum so produced, is obtained by physically modifying the release properties of the antimicrobial agent by coating and drying. The antimicrobial agent is coated by encapsulation, partially coated by agglomeration, entrapped by absorption, or treated by multiple steps of encapsulation, agglomeration, and absorption. The coated antimicrobial agent is preferably then co-dried and particle sized to produce a release-modified antimicrobial agent for use in chewing gum. When incorporated into the chewing gum, these particles are adapted to produce a fast release or a delayed release when the gum is chewed. The preferred antimicrobial agent is chlorhexidine digluconate.

Abstract: Aureobasidium ?-1,3-1,6 glucans and compositions containing such glucans, as well as methods of their preparation. Aureobasidium medium that contains ?-1,3-1,6 glucans, particularly medium produced by Aureobasidium strain FERM P-18099. The ?-glucans of the present invention have a variety of industrial and commercial uses, including applications in pharmaceutical or medical products or treatments, for the removal or control of environmental or microbiological contaminants, in cosmetics, and in nutritional products and foods.

Abstract: A stable form of artemisinin wherein an artelinic acid or artesunic acid is complexed with cyclodextrin analogs, preferably, ?-cyclodextrin. The complexed cyclodextrin artemisinin formulation shields the peroxide portion of the artemisinin backbone from hydrolytic decomposition rendering it stable in solution. Artelinic acid and cyclodextrin are placed into contact with one another to yield a 2:1 molecular species. Artesunic acid and cyclodextrin yield a 1:1 molecular species. The complexed cyclodextrin artemisinin formulation is effective for the treatment of malaria and is stable in solution for long periods of time.

Abstract: A method for producing a chewing gum with a controlled release active agent, as well as the chewing gum so produced, is obtained by physically modifying the release properties of the active agent, such as a nutraceutical or nutritional supplement, by coating and drying. The active agent is coated by encapsulation, partially coated by agglomeration, entrapped by absorption, or treated by multiple steps of encapsulation, agglomeration, and absorption. The coated active agent is preferably then co-dried and particle sized to produce a release-modified active agent for use in chewing gum. The active agent may also be used in a coating on a chewing gum product, as part of a rolling compound applied to the chewing gum product, or as a part of the liquid in a liquid-center chewing gum product.

Abstract: A composition for treatment of bacterial infections of the eye is disclosed which comprises a lytic enzyme composition specific for the infecting bacteria, and a carrier for delivering said lytic enzyme. The carrier for delivering at least one lytic enzyme to the eye may be but is not limited to the use of an isotonic solution.

Abstract: A double-headed, closed-mouth cough suppressant and cold relief device in which an individual having the symptoms of a cough is able to suppress the cough by inserting the device into an open mouth, and by sucking on one end of the device, is able to release a menthol medicament disposed within the device to thereby suppress a cough. Additionally, by sucking on another end of the device a eucalyptus medicament is released to thereby relieve a sore throat. By suppressing the cough, the device prevents the spread of germs to the immediate environment.

Abstract: The present invention relates to chewing gum composition comprising a polymeric surface active agent. A second aspect of this invention relates to a crunchy chewing gum wherein the crunchy texture is provided by particulate polyphosphate particles within the formulation and which lasts through the initial minutes of mastication. The chewing gum composition may also contain a cationic material and or an orally active metallic ion. The chewing gum composition will provide surface conditioning effects on a subject's teeth and or oral mucosa and the crunchy texture is used as a sensate to reinforce these effects. The surface conditioning effects can be measured through in vitro or in vivo testing. The in vitro testing shows a total surface energy and or a lewis base score to increase immediately after treatment with the chewing gum and then decrease over time.

Abstract: The present invention provides a method for skin care by orally administering a skin care agent comprising an ingestible carrier and natural-type N-acetylglucosamine obtainable by hydrolysis of chitin with an acid, an enzyme, or an acid and an enzyme, wherein the natural-type N-acetylglucosamine is contained in an amount of from 0.1 to 99.9% by weight, by which the moisture and tension of skin can be improved and the rough skin and fine wrinkles can be prevented or ameliorated. The skin care agent may be a skin care agent containing chitinoligosaccharide in an amount of from 0.1 to 20% by weight and natural-type N-acetylglucosamine in an amount of from 0.1 to 99.9% by weight; or a skin care agent containing collagen peptide in an amount of from 0.1 to 99.9% by weight and natural-type N-acetylglucosamine in an amount of from 0.1 to 99.9% by weight.

Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof.

Abstract: Topical oral dosage forms containing bismuth compounds are described, which are useful for treating H. pylori and other bacterial infections that cause gastrointestinal disorders and halitosis, as well as for treating ocular and dermal wounds. Methods of employing topical oral dosage forms for treating bacterial infections that cause gastrointestinal disorders and halitosis, and for treating ocular and dermal wounds, are also described.

Abstract: The process entails increasing the concentration of cyclodextrin to 15% (w/w) and above to form complexes through a precipitation process in order to increase the yield of complexes, increase the amount of guest complexed, and decrease the particle size of the complex.

Abstract: The invention concerns improved sugar-free products, their production and use, in particular, coated products, their production and use. The products are characterized by their content in enriched mixtures of 1-O-?-D-glucopyranosyl-D-mannitol (1,1-GPM) and 6-O-?-D-glucopyranosyl-D-sorbitol (1,6-GPS).

Abstract: The present invention relates to a quick-disintegrating tablet in the buccal cavity comprising a drug, a diluent, and a saccharide with a relatively lower melting point than the drug and the diluent, which is obtained by uniformly mixing the saccharide with a low melting point in the tablet so that a bridge will be formed between said drug and/or said diluent particles by the product of melting and then solidification of this saccharide with a low melting point.

Abstract: A gum, lollipop and lozenge having at least two separate components, with at least one of such components containing amounts of herbal, medicinal and/or mineral elements or combinations thereof.

Abstract: An object of the present invention is to provide a coated product with increased stiffness to reduce the chipping after manufacturing and several days of storage, and before wrapping. A coated product such as chewing gum, medicines and medicinal tablets, wherein the product is coated with a coating composition comprising hydrogenated indigestible starch syrup as a binding agent.

Abstract: The present invention is directed to a method for increasing the bone mineralization of a human, and more preferably an infant or toddler. The method comprises administering to said human a source of calcium and a fat blend that is low in palmitic acid. The enhanced mineralization results in the production of a higher peak bone mass and correspondingly lowers the incidence of osteoporosis.

Abstract: The present invention pertains to compositions having improved delivery of pharmaceutical actives. These compositions comprise pharmaceutical actives in an anhydrous solvent. These compositions may take the form of liquid elixirs placed into the mouth and eventually swallowed, or can be delivered via liquid-filled drops, metered liquid dosing devices, atomizers and liquid-releasing, edible capsules.

Abstract: The present invention pertains to a method for providing dental hygiene which method employs a low moisture chewing gum or confectionery product containing as active ingredients, a combination of sodium bicarbonate and casein phosphopeptide-amorphous calcium phosphate. The invention also concerns the chewing gums and confectionery products that can provide dental health benefits and methods for their preparation.

Abstract: A non-food anti-microbial-adhesion and aggregation composition comprising a suitable carrier and an effective amount of an adhesion inhibitory fraction isolated from juice from berries of the Vaccinium plant genus. In an embodiment the anti-aggregation and adhesion fraction is isolated from cranberry juice. It is characterized as being polymeric and having a molecular weight ?14,000; an elemental analysis of carbon 43-51%, hydrogen 4-5%, no nitrogen, no sulfur and no chlorine; a nuclear magnetic resonance (NMR) line spectrum as set forth in FIGS. 2A and 2B; and an ultraviolet spectrum with an absorption peak at 280 nm in neutral or acidic pH solution which is absent in alkali solutions. This fraction exhibits adhesion inhibitory activity against P fimbriated bacteria, oral bacteria and Helicobacter pylori.

Abstract: The present invention is directed to solid and semi-solid formulations of the amino acid L-glutamine. Particular formulations include popsicles, lollipops, oral strips and lozenges, optionally including flavor agents and/or anesthetics and media. Also provided are methods for the treatment of mucositis, particularly that associated with chemo- and radiotherapy for cancer patients.

Abstract: A consumable film adapted to adhere to and dissolve in the oral cavity of a warm-blooded animal including humans, comprising a modified starch, a pharmaceutically active agent and, optionally, at least one water soluble polymer.

Abstract: Various edibles, their compositions, and manufacturing methods therefore are disclosed. Some examples of the edibles include orally soluble films. Some of the films may have a pleasant taste, carry nutraceuticals, carry medication, or serve other purposes.

Abstract: The present invention relates to an edible film composition comprising: a safe and effective amount of a cellulose based film forming agent comprising a mixture of at least one low viscosity cellulose based film forming agent and at least one high viscosity cellulose based film forming agent; a safe and effective amount of a plasticizing agent; and a safe and effective amount of a flavoring agent; wherein the film composition rapidly dissolves in the oral cavity. This invention further relates to a method of increasing film strength of an edible film composition while maintaining rapid film dissolution, by incorporating the above described cellulose based film forming agents into an edible film composition. In one embodiment the edible film is a breath freshening film.

Abstract: The present invention relates to pharmaceutical compositions containing fenofibrate in the form of an inclusion complex with cyclodextrin, having high dissolution profile and in vivo enhanced bioavailability as compared with plain micronized fenofibrate compositions. An inclusion complex has a molar ratio of fenofibrate (preferably in micronized form) to cyclodextrin of from about 1:0.5 to about 1:4, preferably from about 1:1 to about 1:2. The immediate release fenofibrate composition is preferably in the form of a tablet or in the form of granules inside a capsule.

Abstract: A nutritional supplement for providing, and for promoting the health of salivary glands and/or supporting normal or healthy swallowing includes ingredients obtainable from turmeric, ginger, and horseradish. The nutritional supplement may also be used to treat symptoms such as symptoms of a common cold, sore throat, congestion, mucositis, laryngitis, mucous membrane inflammation and sialorrhea, as well as inflammation and viral infectin, or to inhibit or exterminate a virus. This nutritional supplement can be orally administered a person. The nutritional supplement may further include optional ingredients such as ingredients obtainable from slippery elm bark powder and green tea, as well as other optional ingredients. This nutritional supplement may further include a pharmaceutically acceptable carrier for oral administration.

Abstract: The present invention is concerned with a new carbonated candy-type vitamin preparation comprising at least one active ingredient selected from the group consisting fat-soluble vitamins, water soluble vitamins, amino acids, trace inorganic compound, other ingredients necessary for human beings, organic acids; sucrose and; starch syrup(maltose syrup); sodium bicarbonate; and carbon dioxide, with the proviso that at least one vitamin is comprised. Children eagerly take the present vitamin preparation and when the preparation is taken in the mouth, the carbonated pharmaceutical vitamin preparation is popped out and the active ingredients are diffused and dissolved in the mouth very quickly and therefore, the effects of the active ingredients showed very quickly.

Abstract: Fondant-based pharmaceutical compositions comprising active ingredients and dosage forms made therefrom are provided.

Abstract: The present invention provides a composition and methods of using composition consisting essentially of a soy component, chasteberry, clover, and black cohosh, in a suitable carrier, optionally with each of the soy component, chasteberry, clover, and black cohosh is enrobed in a glycoprotein matrix.

Abstract: The invention comprises an oral platform, a microchip for making physiological tests and/or delivery of drugs, and a stick connected to the platform to serve as a handle or conduit from the microchip for exterior communication. A candy shell coating on the platform incorporates medicinal agents. The platform has a plurality of fluidic ports conducive for communication of saliva to or oral delivery from the microchip. A base unit is connected to the stick and communicates to the microchip. The platform, microchip, and stick are combined together into a lollipop and further comprise a plurality of base units which are interchangeable with a plurality of lollipops. A cradle unit capable of is temporarily coupled to the base unit for recharging the base unit. The cradle unit further provides data processing, communication and/or display. The invention is also a method of making physiological tests and/or delivering drugs with the above device.

Abstract: A pain relief lollipop comprises a candy matrix comprising (a) an opioid agonist, (b) an N-methyl-D-aspartate receptor antagonist different from the opioid agonist, and, optionally, a muscle relaxant, sedative, anxiolytic, and/or antidepressant. A patient can self-administer small amounts of the pain relief drug as needed by simply licking or sucking on the lollipop in response to his subjective experience of pain.

Abstract: A dietary supplement, preferably formulated with a confectionery base, removes or prevents the bio-accumulation of heavy metals in the body. The supplement has one or more natural chelators, or precursors therefore, with at least one chelator capable of crossing the blood brain barrier to capture a heavy metal ion from a site in the central nervous system. The chelator then crosses back through the blood brain barrier with the entrained heavy metal ion. Preferably, one or more secondary chelators bind any of the heavy metal released from the primary chelator and hold it for removal via an excretion pathway. In one embodiment, the supplement includes glutathione or metallothionine to assist in moving the chelated heavy metal out into the excretion pathway. Using the dietary supplement limits the accumulation of heavy metals in the body, promotes removal of heavy metals previously accumulated in the body and thereby alleviates the symptoms and conditions associated with heavy metal toxicity.

Abstract: A pharmaceutical formulation comprising one or more active pharmaceutical ingredients (APIs) suitable for intraoral uptake, that comprises cocoa powder, a process for manufacturing the formulation and use of the formulation for medical treatment.

Abstract: Encapsulation compositions in which an encapsulate (A) is encapsulated in a matrix (B) may be prepared by: (i) mixing matrix (B) with a liquid plasticizer and encapsulate (A) in an extruder, to obtain a melted mixture of encapsulate (A) and matrix (B); and (ii) extruding the melted mixture, to obtain an extruded mixture.

Abstract: A dietary supplement for mammalian consumption, and particularly human consumption, for the purpose of stimulating the immune system, inhibiting infection and increasing tissue repair and healing. Comprising colostrum, lactoferrin, and with modified citrus pectin as an optional component, the dietary supplement is administered in ‘mucosal delivery format’: a dosage form that promotes effective absorption through the lining of the oral cavity.

Abstract: Methods and products for delivering a medicament or agent to an individual are provided. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a center comprising a gum base. By chewing the product, the medicament or agent is released from the product. Continuing to chew the product creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

Abstract: The invention relates to oral care compositions such as toothpaste, gels, tooth powders, mouthwashes, mouth rinses, gums, such as chewing gum, mouth sprays and lozenges comprising diglycerol. The diglycerol is used as a humectant in the compositions. The compositions may further comprise water, flavoring agents, active compounds, emulsifier, alcohol, sweeteners, thickening agents, surfactants, suspending agents, astringent and toning drug extracts, flavor correctants, abrasives or polishes, deodorizing agents, preservatives, flavoring buffers, whitening agents, wound-healing and inflammation inhibiting substances, colorants, dyes, pigments, abrasives, polishes, antimicrobial agents, pH buffers and other additives and fillers.

Abstract: The present invention provides stable formulations of ACE inhibitors, especially enalapril maleate, that can be manufactured in a time efficient, cost effective manner. Such formulations can be prepared simply and on a large industrial scale. The present invention also provides methods for the preparation of stable formulations of ACE inhibitors, especially enalapril maleate.

Abstract: A food item, preferably a bar of chocolate, that has a phosphatidyl serine content of 100 mg to 300 mg and a relatively high carbohydrate content.

Abstract: Disclosed is an improved composition and method for smoking cessation. The composition includes a candy base, sweetener, nicotine, (to satisfy nicotine cravings experienced by someone attempting to discontinue smoking), and chromium picolinate, (to address the issue of undesirable weight gain associated with smoking cessation.) The method includes selective substitution of the lollipop with the cigarette until smoking ceases.

Abstract: A composition for the control of smoking which comprises: (a) a flavonoid in the form of an extract from Eupatorium cannibium or Eupatorium Fortunei, preferably euparin; (b) a cytochrome P450 inhibitor; (c) a sugar; (d) a source of phosphate; and, optionally, (e) one or more pharmaceutically acceptable carriers.

Abstract: A gum based chewing product, particularly a chewing/bubble gum, contains a synthetic or natural betel nut source, an alkaloid-like composition such as nicotine or other such alkaloids like caffeine, theine etc. from natural or synthetic origin for its source. The product preferably has taste enhancers like lime and/or catechu. A process for preparing the gum based chewing product. The product has improved high smoothness, less saliva generation, excellent overall taste and chewing properties. The gum pieces deliver 1 to 12.6 mg of nicotine per piece.

Abstract: Quickly disintegrating solid preparations which contain: a) an active ingredient; b) D-mannitol having an average particle size of 30 &mgr;m to 300 &mgr;m; c) a disintegrating agent; and d) celluloses.

Abstract: A highly safe bone resorption suppressing agents, which can be used as medicines or admixed to food products or feeds, is produced. Milk-derived basic cystatins and/or milk-derived basic cystatin decomposition products prepared from milk are made into bone resorption suppressing agents, or admixed to drinks, food products and feeds.

Abstract: A lozenge for the treatment of Hemophilus influenzae infections of the mouth throat and nasal passage is disclosed which comprises a lytic enzyme composition specific for Hemophilus influenzae, and a lozenge carrier for delivering said lytic enzyme.

Abstract: Beta-glucan soluble fiber and non-digestible fats are administered orally to reduce blood cholesterol levels and to control postprandial blood glucose and insulin levels. The beta-glucan soluble fiber and non-digestible fat may be administered as separate compounds, as a mixture, or combined with other materials and administered in the form of an appealing food.

Abstract: Disclosed are stable portable oral care confectionery compositions which provide enhanced oral malodour benefits. Compositions of the present invention can optionally have one or more additional oral care benefits. The confectionery compositions comprise: (i) greater than about 10 ppm of a first metal cation selected from the metals of groups 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 of the periodic table; (ii) greater than about 10 ppm of a second metal cation different from the first metal cation and selected from the metals of groups 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 of the periodic table; (iii) less than about 10% water; and (iv) a confectionery carrier wherein the ratio of the first metal cation to the second metal cation is in the range of from about 50:1 to about 1:50.

Abstract: Disclosed are stable portable oral care confectionery compositions which provide enhanced oral malodour benefits combined with enhanced anti-calculus benefits, wherein the confectionery compositions comprise: (i) a polyphosphate material with an average anion chain length of greater than or equal to 3; (ii) greater than about 10 ppm of a metal cation selected from the metals of groups 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 of the periodic table; (iii) less than about 10% water; and (iv) a suitable confectionery carrier material wherein the ratio of polyphosphate anion to metal cation is in the range of from about 10:1 to about 1:1.